Hagens Berman Continues Abiomed Investigation into Possible Securities Law Violations on Behalf of Investors


Hagens Berman, an investor-rights law firm, is continuing to investigate Abiomed Inc. (NASDAQ:ABMD) regarding possible securities law violations following the company’s disclosure of a Department of Justice (DOJ) probe into the marketing and labeling of its flagship product, the Impella 2.5 system.

LOADING PDF: If there are any problems, click here to download the file.